Nykode Therapeutics ASA (NYKD) — Capital Reinvestment Ratio
Nykode Therapeutics ASA (NYKD) has a Capital Reinvestment Ratio of 0.15x as of March 2022, meaning it reinvests 0% of its operating cash flow (Nkr96.14 Million) in capital expenditures (Nkr14.06 Million). Check Nykode Therapeutics ASA tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Nykode Therapeutics ASA Capital Reinvestment Ratio (2020–2021)
This chart tracks Nykode Therapeutics ASA's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see Nykode Therapeutics ASA cash flow conversion.
Annual Capital Reinvestment Ratio for Nykode Therapeutics ASA (2020–2021)
Year-by-year Capital Reinvestment Ratio for Nykode Therapeutics ASA from 2020 to 2021. See NYKD free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (NOK) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.75x | Nkr1.16 Million | Nkr871.00K | ▲ +137214.0% |
| 2020 | 0.00x | Nkr180.27 Million | Nkr99.00K | — |